Sign in
Taking people in South KoreaPhase 1/2

Ifinatamab deruxtecan for children with solid tumors that came back or did not respond

Tests ifinatamab deruxtecan in children whose solid tumors returned or resisted treatment.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Seoul, South KoreaSee the 2 sitesAlso in 14 other countries, 43 sites
Trial code
Registry title
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Status
Recruiting
Phase
Phase 1/2
People taking part
134 people, planned
Started
6 Jul 2026
Expected to end
17 Aug 2031
Type of study
Interventional
Treatments tested
  • Ifinatamab Deruxtecan
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers whose solid tumor came back or did not respond to earlier treatment, and who have no other satisfactory treatment option.

Age
From 1 month to under 12 years in Part 1. From 1 month to under 18 years in Part 2.
Sex
Any sex or gender can join.
Disease stage
Relapsed or refractory solid tumor, not a primary tumor of the central nervous system (CNS). In Part 2 the tumor must be confirmed as osteosarcoma, neuroblastoma, rhabdomyosarcoma or Wilms tumor. The disease must have grown on scans after at least 1 earlier line of treatment.
Earlier treatment
At least 1 earlier line of treatment for locally advanced or metastatic disease, with no satisfactory alternative treatment option. Side effects from earlier cancer treatment must have improved to Grade 1 or baseline.

Main reasons for not taking part

  • Clinically significant corneal disease
  • Any history of interstitial lung disease or pneumonitis (except radiation pneumonitis that needed no steroids)
  • History of solid organ transplant or allogeneic stem cell transplant
  • History of HIV infection
  • Known active CNS metastases or carcinomatous meningitis

The registry criteria, word for word

Show all 18 criteriaShow less

Other criteria

  • The main inclusion criteria include but are not limited to the following:
  • In Part 1, participant has recurrent or relapsed, refractory solid tumors (excluding primary central nervous system (CNS)); and in Part 2, participant has recurrent or relapsed, refractory and histologically confirmed diagnosis of osteosarcoma (OST), neuroblastoma (NBL), rhabdomyosarcoma (RMS), or Wilms tumor (WT). All participants must meet the following criteria: Has documented radiological disease progression after at least 1 line of prior therapy in the locally advanced/metastatic setting and who has no satisfactory alternative treatment option (ie, is ineligible for other standard treatment regimens)
  • Is an individual of any sex/gender, ≥1 month to <12 years of age for Part 1 and ≥1 month to <18 years for Part 2 at the time of providing the informed consent or assent, as applicable
  • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible; The main exclusion criteria include but are not limited to the following:
  • Has clinically significant corneal disease
  • Has a history of cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event within 6 months before screening
  • Has uncontrolled or significant cardiovascular disease, including conduction abnormalities, hypertension, ischemic heart disease, heart failure, and peripheral vascular disease
  • Has any history of interstitial lung disease (ILD)/pneumonitis, irrespective of steroid use, except for a history of radiation pneumonitis that did not require steroids, current ILD, or Clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illnesses
  • Has an active, known or suspected autoimmune disease
  • Has history of solid organ transplant
  • Has history of allogeneic stem cell transplant (SCT)
  • Has known active CNS metastases and/or carcinomatous meningitis/leptomeningeal disease/spinal cord compression. Participants with untreated and asymptomatic brain metastases or previously treated brain metastases may participate provided they are radiologically stable, (i.e, without evidence of progression) for at least 4 weeks
  • Has history of human immunodeficiency virus (HIV) infection
  • Has known additional malignancy that is progressing or has required active treatment within the past 1 year
  • Has active infection requiring systemic therapy
  • Has known hypersensitivity or contraindication to either the study intervention substance or inactive ingredients in the study intervention product
  • Participants who have not adequately recovered from major surgery or have ongoing surgical complications

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • What type of cancer has the patient been diagnosed with?
  • Is this cancer newly diagnosed, or has it come back or not responded to treatment?

Where in South Korea

Also in 14 other countries, 43 sites

  • Asan Medical Center-Pediatrics - Pedicatric Oncology (Site 4973)Seoul, South KoreaContact: Study CoordinatorTaking people
  • Seoul National University Hospital-Pediatrics (Site 4972)Seoul, South KoreaContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers are looking for new ways to treat children with relapsed or refractory solid tumors:

Read full original descriptionShow less

* Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids

The study treatment I-DXd (also known as MK-2400 or ifinatamab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn:

* About the safety of I-DXd and if children younger than 12 years old tolerate it * How many children who receive I-DXd have the cancer get smaller or go away

The group in the trial

  • Ifinatamab DeruxtecanTreatment being tested

    Participants receive ifinatamab deruxtecan via intravenous (IV) infusion on day 1 of each 3-week cycle until discontinuation or progression

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Plain-language title
Ifinatamab deruxtecan for children with solid tumors that came back or did not respondGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07630974, who can take part
Record updated
30 October 2026